What is Hepion Pharmaceuticals Inc (HEPA)?

Hepion Pharmaceuticals Inc (HEPA) Stock Analysis

$0.318

-0.060 (-18.79%)At close

Loading chart…

High: 0.414
Open: 0.385
VWAP: 0.35
Vol: 4.37M
Mkt Cap: 6.02M
Low: 0.310
Amount: 1.52M
EV/EBITDA, TTM: 0.00

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company's cyclophilin inhibitor, rencofilstat is developed to offer benefits to address multiple complex pathologies relate to advanced liver disease. The Company’s rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company provides an artificial intelligence (AI) tool, AI-POWR, that allows the selection of novel drug targets, biomarkers, and appropriate patient populations. The components of AI-POWR include access to publicly available databases, and in-house genomic and multi-omic big.

hepionpharma.com

Valuation Metrics

The current forward P/E ratio for Hepion Pharmaceuticals Inc (HEPA) is -0.00, compared to its 5-year average forward P/E of -0.76.

Forward P/E

Fair

5Y Average P/E

-0.76

Current P/E

-0.00

Overvalued

0.04

Undervalued

-1.56

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

0.03

Current EV/EBITDA

0.00

Overvalued

0.16

Undervalued

-0.10

Forward P/S

Fair

5Y Average P/S

0.74

Current P/S

0.00

Overvalued

5.58

Undervalued

-4.09

Events Timeline

2026-03-03 (ET)